Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
Michelle E Keyel,1,2 C Patrick Reynolds1–4 1Cancer Center, 2Department of Pediatrics, 3Department of Internal Medicine, 4Department of Cell Biology & Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA Abstract: Neuroblastoma (N...
Saved in:
Main Authors: | Keyel ME, Reynolds CP |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2018
|
Subjects: | |
Online Access: | https://doaj.org/article/54f44a9d7f4444ea894f7bcee0cad1d9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Monoclonal Antibody Therapies for High Risk Neuroblastoma
by: Furman WL
Published: (2021) - Monoclonal antibodies in immunodiagnosis and immunotherapy
-
A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy
by: Zhang L, et al.
Published: (2021) -
Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor
by: Orienti I, et al.
Published: (2020) -
Neuroblastomas en el niño
by: E,BAUZA, et al.
Published: (1950)